-
Contouring aid tools in radiotherapy. Smoothing: the false friend Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-17 Jordi Marruecos Querol, Diego Jurado-Bruggeman, Anna Lopez-Vidal, Ricard Mesía Nin, Jordi Rubió-Casadevall, Maria Buxó, Aranzazu Eraso Urien
-
Association between thyroid disorders and extra-thyroidal cancers, a review Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-15 Xin Jia, Jingru Li, Zongliang Jiang
-
The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-15 Bingbing Yang, Xiaoqi Xin, Xiaoqing Cao, Lubanga Nasifu, Zhenlin Nie, Bangshun He
-
Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-15 Jie Ma, Tao Chen, Jianning Zhang, Weidong Cao, Gan Gao, Xinguang Yu, Hongwei Wang
-
Assessment of TUFT1 and Rac1-GTP levels in triple-negative breast cancer patients: clinical and pathological correlations Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-13 Su-fang Shi, Rui-xi Cai, Yan-fei Ren, Yong Li, Shuo Li, Tian-lu Yin, Dong-xiao Jia, Yong-jun Li
-
Clinical risk prediction model and external validation of positive surgical margin in laparoscopic radical prostatectomy based on MRI lesion location Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-13 Xin Chen, Chaozhong Wang, Yongchang Chen, Chengbo Qian, Renpeng Huang, Jie Bao, Yuxin Lin, Jianquan Hou, Yuhua Huang, Xuedong Wei
-
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-13 Yuanliang Zhou, Jingchao Li, Yankang Li, Guangchuan Deng, Qi Wang, Hongyue Qin, Jianbin Li, Zhenxiang Li
-
Sarcopenia among treated cancer patients before and after neoadjuvant chemotherapy: a systematic review and meta‐analysis of high-quality studies Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Yuanhao Su, Yongke Wu, Cheng Li, Tingkai Sun, Yunhao Li, Zhidong Wang
-
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
-
Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Juanyi Shi, Kai Wen, Sintim Mui, Huoming Li, Hao Liao, Chuanchao He, Yongcong Yan, Zhenyu Zhou, Zhiyu Xiao
-
A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Ranita Pal, Trisha Choudhury, Madhurima Ghosh, Manisha Vernakar, Partha Nath, Vilas Deorao Nasare
-
Computed tomography-based radiomics nomogram for predicting therapeutic response to neoadjuvant chemotherapy in locally advanced gastric cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-11 Wenjing Chen, Weiteng Zhang, Xietao Chen, Weisong Dong, Yiqi Cai, Jun Cheng, Jinji Jin
-
Prognostic value of dynamic changes of pre- and post-operative tumor markers in colorectal cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-07 Guangming Ren, Gaozan Zheng, Kunli Du, Zhangfeng Dang, Hanjun Dan, Xinyu Dou, Lili Duan, Zhenyu Xie, Liaoran Niu, Ye Tian, Jianyong Zheng, Fan Feng
-
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-07 Serhat Sekmek, Irfan Karahan, Gokhan Ucar, Furkan Ceylan, Dogan Bayram, Ismet Seven, Hatice Bölek, Yüksel Ürün, Kadriye Bir Yücel, Ozan Yazici, Ahmet Kadioglu, Cengiz Karacin, Kubra Canaslan, Elif Atag, Serhat Demirer, Gokmen Umut Erdem, Yakup Ergun, Mehmetcan Atak, Baris Koksal, Merve Meryem Kiran, Duriye Ozer Turkay, Burak Civelek, Bulent Yalcin, Dogan Uncu
-
Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-07 Xiaoming Wang, Dayu Chen, Yuyan Ma, Dongping Mo, Feng Yan
-
SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-02 María-Carmen Rubio Rodríguez, Xin Chen-Zhao, Ovidio Hernando, Sonia Flamarique, Pedro Fernández-Letón, Maider Campo, Mercedes López, Maitane Rodríguez, Daniel Zucca, Daniel Martínez, Emilio Sánchez-Saugar, Fernando Mañeru, Juan García Ruiz-Zorrilla, Paz García de Acilu, Jeannette Valero, Angel Montero, Raquel Ciérvide, Beatriz Alvarez, Mariola García-Aranda, Rosa Alonso, Miguel Angel de la Casa, Leyre
-
MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-02 Na Wang, Yuan Zhang, Junhua Wu, Yili Zhu, Ying Wu, Bo Huang, Ruiguang Zhang, Jun Fan, Xiu Nie
-
Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-01 Hui Rao, Qi Wang, Xiaoli Zeng, Xuejiao Wen, Li Huang
-
Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-13
Abstract Cancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk of bleeding while anticoagulated. In addition, cancer therapies have been associated to increased VTE risk. Guidelines for VTE treatment in cancer patients recommend low molecular weight heparins (LMWH) or direct oral anticoagulants (DOAC) for the initial treatment, DOAC for VTE short-term treatment
-
Towards stronger tobacco control policies to curb the smoking epidemic in Spain Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-12 Mónica Pérez-Ríos, Jasjit Ahluwalia, Carla Guerra-Tort, Guadalupe García, Julia Rey-Brandariz, Nerea Mourino-Castro, Ana Teijeiro, Raquel Casal-Fernández, Iñaki Galán, Leonor Varela-Lema, Alberto Ruano-Ravina
Smoking and exposure to secondhand smoke pose a significant risk to the health of populations. Although this evidence is not new, the commitment of countries to implement laws aimed at controlling consumption and eliminating exposure to secondhand smoke is uneven. Thus, in North America or in Europe, locations like California or Ireland, are pioneers in establishing policies aimed at protecting the
-
Criteria and indicators to evaluate quality of care in genitourinary tumour boards Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-11 Javier Puente, Ferrán Algaba Arrea, Óscar Buisán Rueda, Daniel Castellano Gauna, Ignacio Durán, Juan José Fernández Ávila, Alfonso Gómez-Iturriaga, Mariano José Parada Blázquez, Daniel Pérez Fentes, Gemma Sancho Pardo, Juan Antonio Vallejo Casas, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta
-
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-09 Eva Ciruelos, Jose Ángel García-Sáenz, Joaquín Gavilá, Miguel Martín, César A. Rodríguez, Álvaro Rodríguez-Lescure
-
Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-08 Mónica Guillot Morales, Laura Visa, Elena Brozos Vázquez, Jaime Feliu Batlle, Parham Khosravi Shahi, Berta Laquente Sáez, Borja López de San Vicente Hernández, Teresa Macarulla, Regina Gironés Sarrió
-
What’s new about the tumor microenvironment of urothelial carcinoma? Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-08 João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões, Sérgio Xavier Azevedo, Joana Febra, António Araújo
-
Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-08 Shanshan Ding, Shasha Xiong, Xueli Wang, Changdong Zhang, Song Chen, Ming Sun, Chunlin Wu, Xiong Zhang, Meiying Wang, Jia Wang, Xiaoke Shang
-
Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-08 Hanxiao Chen, Xiangjuan Ma, Jie Liu, Yu Yang, Yanhui He, Yong Fang, Liping Wang, Jian Fang, Jun Zhao, Minglei Zhuo
-
Impact of anthracycline-based chemotherapy on RB1 gene methylation in peripheral blood leukocytes and biomarkers of oxidative stress and inflammation in sarcoma patients Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-03
Abstract Purpose We investigated the impact of anthracycline-based chemotherapy on methylation status of RB1 gene in peripheral blood leukocytes together with parameters of oxidative stress and inflammation in sarcoma patients. Patients/methods Blood samples were collected from 51 consecutive newly diagnosed sarcoma patients admitted to University Hospital Center Zagreb (Zagreb, Croatia) for first-line
-
Doxorubicin-induced chemoresistance in Duke’s type B colon adenocarcinoma cell line is aggravated in the presence of TGF-β2 through non-apoptotic cell death Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-03 Sruthi Sritharan, Nageswaran Sivalingam
-
Surface guided radiation therapy with an innovative open-face mask and mouth bite: patient motion management in brain stereotactic radiotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-01 Xuemei Chen, Lu Liu, Yajuan Wang, Xiaotong Huang, Weixun Cai, Xiaodong Rong, Liuwen Lin, Jindi Liu, Xiaobo Jiang
-
Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-02-01 Fengxiang Huang, Haiyan Yang, Wenguang Bao, Yehong Bin, Shengsheng Zhou, Man Wang, Xiaoping Lv
-
CAR-T cell therapy: a game-changer in cancer treatment and beyond Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-20 Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Khan, Gunjan Dagar, Mukesh Kumar, Mayank Singh, Shabirul Haque
-
Radiation-induced changes in gene expression in rectal cancer specimens Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-19
Abstract Purpose The standard-of-care for locally advanced rectal cancer is radiotherapy-based neoadjuvant therapy followed by surgical resection. This article reviews the evidence of molecular changes at the transcriptome level induced through radiotherapy in rectal cancer. Methods The PubMed search “(radiation OR radiotherapy) cancer (transcriptome OR “gene expression”) rectal” was used. The studies
-
Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-16 Liming Zhao, Jun Li, Zhongguang Xue, Jinfeng Wang
-
Surgical margins and prognosis of borderline and malignant phyllodes tumors Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-13 Jialin Su, Shanling Liu, Gang Tu, Fangxuan Li, Jie Zhang, Lu Gan
-
Changes in the fecal microbiota of breast cancer patients based on 16S rRNA gene sequencing: a systematic review and meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-13 Biqing Luan, Fei Ge, Xingjia Lu, Zhiqiang Li, Hong Zhang, Jingxuan Wu, Qizhi Yang, Liang Chen, Wenzhu Zhang, Wenlin Chen
-
Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-11
Abstract Purpose Biomarkers as screening for precision medicine is a fundamental step. The purpose of this article is twofold. First, to highlight the existing barriers in the implementation of Precision Medicine in Spain, with a special emphasis on barriers in access to the determination of biomarkers. Second, to provide a Roadmap that can help implement Precision Medicine equitably at the national
-
Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-11 Dong-Ming Li, Guo-Sheng Li, Jian-Di Li, Feng Chen, Hong Huang, Wan-Ying Huang, Zhi-Guang Huang, Yi-Wu Dang, Yu-Lu Tang, Zhong-Qing Tang, Wen-Jia Tang, Gang Chen, Hui-Ping Lu
-
Depression promotes breast cancer progression by regulating amino acid neurotransmitter metabolism and gut microbial disturbance Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-09 Sisi Lin, Zhe Zhou, Yiming Qi, Jiabing Chen, Guoshu Xu, Yunfu Shi, Zhihong Yu, Mingqian Li, Kequn Chai
-
Using Vision Transformer for high robustness and generalization in predicting EGFR mutation status in lung adenocarcinoma Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-09
Abstract Background Lung adenocarcinoma is a common cause of cancer-related deaths worldwide, and accurate EGFR genotyping is crucial for optimal treatment outcomes. Conventional methods for identifying the EGFR genotype have several limitations. Therefore, we proposed a deep learning model using non-invasive CT images to predict EGFR mutation status with robustness and generalizability. Methods A
-
The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-08
Abstract Purpose Systemic immune-inflammatory markers have a certain predictive role in pathological complete response (pCR) after neoadjuvant treatment (NAT) in breast cancer. However, there is a lack of research exploring the predictive value of markers after treatment. Methods This retrospective study collected data from 1994 breast cancer patients who underwent NAT. Relevant clinical and pathological
-
Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-08 Siqi Zhou, Guoxin Cai, Xue Meng, Mengying Li, Ying Fu, Xiaohan Wang, Kaiyue Wang, Xiao Han
-
Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1 Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-08
Abstract Background The significant clinical benefits of PD-1/PD-L1 immune checkpoint inhibitors (ICIP) in non-small cell lung cancer (NSCLC) have been widely recognized, emphasizing the urgent need for a reliable biomarker. In this study, we find the remarkable capacity of tumor mutational burden (TMB) to serve as an accessible and streamlined indicator. Patients and methods We designed a retrospective
-
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-06 Mariano Provencio-Pulla, Diego Pérez-Parente, Sara Olson, Haroon Hasan, Begoña Campos Balea, Delvys Rodríguez-Abreu, Marta López-Brea Piqueras, Navdeep Pal, Samantha Wilkinson, Esther Vilas, Pedro Ruiz-Gracia, Manuel Cobo-Dols
-
Senescence in head and neck squamous cell carcinoma: relationship between senescence-associated secretory phenotype (SASP) mRNA expression level and clinicopathological features Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-04 Kamila Ostrowska, Patryk Niewinski, Igor Piotrowski, Julia Ostapowicz, Sabina Koczot, Wiktoria Maria Suchorska, Paweł Golusiński, Michal Mateusz Masternak, Wojciech Golusiński
-
Transarterial embolization followed by staged hepatectomy versus emergency hepatectomy for ruptured HCC: a meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-01 Tianfan Pan, Feng Gao, Xiangzhong Huang, Xinjian Xu
-
Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in Mexico Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-01 Mariana Molina-Jaimes, Antonio Galindo-González, Haydeé Cristina Verduzco-Aguirre, Sergio Bautista-Arredondo, Gustavo Reyes-Terán, Enrique Soto-Perez-de-Celis
-
Which is the appropriate surgical procedure for appendiceal adenocarcinoma: appendectomy, partial colectomy or right hemicolectomy? Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-01 Bochao Zhao, Zhicheng Ma, Jingchao Wang, Weiqiang Wang, Tao Yang, Kewei Meng
-
Delivery of SIRT1 by cancer-associated adipocyte-derived extracellular vesicles regulates immune response and tumorigenesis of ovarian cancer cells Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-01-01 Qingling Zheng, Xiuluan Du, Jin Zhang, Yanxiang Liu, Weijia Dong, Xin Dai, Donghua Gu
-
Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-25 Yuanyuan Cheng, Zhe Ye, Yanru Xie, Xuedan Du, Siqi Song, Xiaobo Ding, Chuchu Lin, Bin Wang, Wenfeng Li, Chunhong Zhang
-
A novel prognostic model for predicting patient survival and immunotherapy responsiveness in hepatocellular carcinoma: insights into the involvement of T-cell proliferation Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-21
Abstract Background The cancer-associated biological mechanisms and the implementation of immunotherapy are heavily impacted by the activities of T cells, consequently influencing the effectiveness of therapeutic interventions. Nevertheless, the mechanistic actions of T-cell proliferation in response to immunotherapy and the overall prognosis of individuals diagnosed with hepatocellular carcinoma (HCC)
-
Cardiovascular comorbidities and their prognostic value in small cell lung cancer patients with chemoradiotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-16 Hanyang Liang, Tianjie Wang, Dong Liu, Hao Wang, Zhengqing Ba, Ying Xiao, Yilu Liu, Jiansong Yuan, Weixian Yang
-
MicroRNA-128 acts as a suppressor in the progression of gastrointestinal stromal tumor by targeting B-lymphoma Mo-MLV insertion region 1 Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-16 Jinbao Wu, Changjuan Wang, Xia Cui, Lin Liu, Lu Wang, Jing Wang, Xiaohui Xue, Tong Dang
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-15 Miguel Ángel Climent, Carlos Álvarez, Rafael Morales, Pablo Maroto, Alejo Rodríguez-Vida, María José Méndez-Vidal, Xavier García del Muro, Javier Puente, Nuria Láinez, Sergio Vázquez, Daniel Castellano, Carmen Gómez Lang, Jing Wang, Alessandra di Pietro, Craig Davis, Belén Sanz-Castillo, M. Victoria Bolós, Begoña P. Valderrama
-
High-grade transformation of head and neck adenoid cystic carcinoma demonstrates distinctive clinicopathological features and an unfavorable prognosis: a matched case-control study of the largest series in China Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-14 Ting-yao Ma, Jun Wu, Shi-zhi He, Xue-lian Wang, Guo-liang Yang, Shu-jing Zhang, Jin Zhou, Yi-ming Ding, Li-feng Li, Hong-fei Liu, Lan-lan Xuan, Xiao-hong Chen
-
Transforming growth factors β and their signaling pathway in renal cell carcinoma and peritumoral space—transcriptome analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-12 Dariusz Kajdaniuk, Dorota Hudy, Joanna Katarzyna Strzelczyk, Krystyna Młynarek, Szymon Słomian, Andrzej Potyka, Ewa Szymonik, Janusz Strzelczyk, Wanda Foltyn, Beata Kos-Kudła, Bogdan Marek
-
Comparing the survival rates of patients with stage IIIC endometrial cancer undergoing sandwich therapy to those undergoing sequential chemotherapy and radiotherapy: a meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-11 Meng-Meng Zhang, Yu-Kun Chen, Li Shi, Jing Ma, Jing-De Jia, Xi-Wa Zhao
-
Correction to: The mechanism of VCP‑mediated metastasis of osteosarcoma based on cell autophagy and the EMT pathway Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-09 An An Li, Yu Zhang, Fan Li, Yang Zhou, Zhi li Liu, Xin Hua Long
-
Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-09 Danjie He, Yudong Zhang, Shuiqing He, Yuzhuo Zhang, Keyao Dai, Cheng Xu, Ying Huang
-
Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist’s perspective Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-09 Carlos Ayala-de Miguel, Jerónimo Jiménez-Castro, Adrián Sánchez-Vegas, Sebastián Díaz-López, Manuel Chaves-Conde
Appendiceal mucinous lesions’ classification and nomenclature has been modified several times along the last decades, reflecting their great heterogeneity and making difficult to compare results and draw conclusions. Despite its nearby origin, appendiceal mucinous lesions have a distinctive behaviour compared to colorectal cancer, including their molecular and genetic markers. Due to their low frequency
-
Validation of prognostic and predictive value of total tumoral load after primary systemic therapy in breast cancer using OSNA assay Clin. Transl. Oncol. (IF 3.4) Pub Date : 2023-12-09 Laia Bernet-Vegué, Carolina Cantero-González, Magdalena Sancho de Salas, David Parada, Tiziana Perin, Zulma Quintero-Niño, Begoña Vieites Pérez-Quintela, Douglas Sánchez-Guzmán, Marina Castelvetere, David Hardisson Hernaez, María Dolores Martín-Salvago